林业发展局在成功试验后,对新的血癌药物Iopofosine I 131给予突破性地位。 FDA grants breakthrough status to new blood cancer drug, iopofosine I 131, after successful trials.

美国食品和药物管理局已授予一种新药,即iopofosine I 131的突破性治疗指标,用于治疗复发性/耐药的沃尔登斯特罗姆巨型球蛋白血症,一种类型的血液癌症. The FDA has granted breakthrough therapy designation to a new drug, iopofosine I 131, for treating relapsed/refractory Waldenström macroglobulinemia, a type of blood cancer. 这一决定是在第二阶段试验数据显示总体回复率为83.6%之后作出的。 This decision follows phase 2 trial data showing an overall response rate of 83.6%. 该药物的开发商细胞切片生物科学目前正在欧洲寻求批准,其库存在市场前交易中猛增71%。 Cellectar Biosciences, the drug's developer, is now seeking approval in Europe and saw its stock surge by 71% in pre-market trading.